{"pmid":32329380,"title":"Adipose-Derived Stromal Stem Cells (ASCs) as a new regenerative immediate therapy combating Coronavirus (COVID-19)-Induced Pneumonia.","text":["Adipose-Derived Stromal Stem Cells (ASCs) as a new regenerative immediate therapy combating Coronavirus (COVID-19)-Induced Pneumonia.","Expert Opin Biol Ther","Gentile, Pietro","Sterodimas, Aris","32329380"],"journal":"Expert Opin Biol Ther","authors":["Gentile, Pietro","Sterodimas, Aris"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329380","week":"202017|Apr 20 - Apr 26","doi":"10.1080/14712598.2020.1761322","keywords":["adipose-derived stem cells coronavirus","cellular therapy covid-19","mesenchymal stem cells covid-19","mesenchymal stem cells coronavirus","stem cell therapy covid-19"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Pneumonia"],"_version_":1664996914892898304,"score":8.518259,"similar":[{"pmid":32257554,"pmcid":"PMC7069463","title":"Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia.","text":["Mesenchymal Stem Cell Infusion Shows Promise for Combating Coronavirus (COVID-19)- Induced Pneumonia.","A new study published by the journal Aging & Disease reported that intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with coronavirus disease 2019 (COVID-19) resulted in improved functional outcomes (Leng et al., Aging Dis, 11:216-228, 2020). This study demonstrated that intravenous infusion of MSCs is a safe and effective approach for treating patients with COVID-19 pneumonia, including elderly patients displaying severe pneumonia. COVID-19 is a severe acute respiratory illness caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, treating COVID-19 patients, particularly those afflicted with severe pneumonia, is challenging as no specific drugs or vaccines against SARS-CoV-2 are available. Therefore, MSC therapy inhibiting the overactivation of the immune system and promoting endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection found in this study is striking. Additional studies in a larger cohort of patients are needed to validate this therapeutic intervention further, however.","Aging Dis","Shetty, Ashok K","32257554"],"abstract":["A new study published by the journal Aging & Disease reported that intravenous administration of clinical-grade human mesenchymal stem cells (MSCs) into patients with coronavirus disease 2019 (COVID-19) resulted in improved functional outcomes (Leng et al., Aging Dis, 11:216-228, 2020). This study demonstrated that intravenous infusion of MSCs is a safe and effective approach for treating patients with COVID-19 pneumonia, including elderly patients displaying severe pneumonia. COVID-19 is a severe acute respiratory illness caused by a new coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently, treating COVID-19 patients, particularly those afflicted with severe pneumonia, is challenging as no specific drugs or vaccines against SARS-CoV-2 are available. Therefore, MSC therapy inhibiting the overactivation of the immune system and promoting endogenous repair by improving the lung microenvironment after the SARS-CoV-2 infection found in this study is striking. Additional studies in a larger cohort of patients are needed to validate this therapeutic intervention further, however."],"journal":"Aging Dis","authors":["Shetty, Ashok K"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32257554","week":"202015|Apr 06 - Apr 12","doi":"10.14336/AD.2020.0301","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"_version_":1664640769729757184,"score":122.82379},{"pmid":32283815,"title":"Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use.","text":["Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use.","From the end of 2019, the world population has been faced the spread of the novel coronavirus SARS-CoV-2 responsible for COVID-19 infection. In approximately 14% of the patients affected by the novel coronavirus, the infection progresses with the development of pneumonia that requires mechanical ventilation. At the moment, there is no specific antiviral treatment recommended for the COVID-19 pandemic and the therapeutic strategies to deal with the infection are only supportive. In our opinion, mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 pneumonia, due to the broad pharmacological effects it shows, including anti-inflammatory, immunomodulatory, regenerative, pro-angiogenic and anti-fibrotic properties.","Cells","Bari, Elia","Ferrarotti, Ilaria","Saracino, Laura","Perteghella, Sara","Torre, Maria Luisa","Corsico, Angelo Guido","32283815"],"abstract":["From the end of 2019, the world population has been faced the spread of the novel coronavirus SARS-CoV-2 responsible for COVID-19 infection. In approximately 14% of the patients affected by the novel coronavirus, the infection progresses with the development of pneumonia that requires mechanical ventilation. At the moment, there is no specific antiviral treatment recommended for the COVID-19 pandemic and the therapeutic strategies to deal with the infection are only supportive. In our opinion, mesenchymal stem cell secretome could offer a new therapeutic approach in treating COVID-19 pneumonia, due to the broad pharmacological effects it shows, including anti-inflammatory, immunomodulatory, regenerative, pro-angiogenic and anti-fibrotic properties."],"journal":"Cells","authors":["Bari, Elia","Ferrarotti, Ilaria","Saracino, Laura","Perteghella, Sara","Torre, Maria Luisa","Corsico, Angelo Guido"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32283815","week":"202016|Apr 13 - Apr 19","doi":"10.3390/cells9040924","keywords":["covid-19","sars-cov-2","acute respiratory distress syndrome","exosomes","extracellular vesicles","mesenchymal stem cells","microvesicles","secretome"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636391551664128,"score":86.97079},{"pmid":32296777,"pmcid":"PMC7147223","title":"Mesenchymal stem cells and management of COVID-19 pneumonia.","text":["Mesenchymal stem cells and management of COVID-19 pneumonia.","Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with rapid virus replication. Arising in Wuhan China December 2019, the current COVID-19 epidemic has rapidly grown with person-to-person infection expanding to become a global health emergency now on pandemic scale. Governments will not be able to minimise both deaths from COVID-19 and the economic impact of viral spread in mitigation of this current COVID-19 pandemic, according to Anderson et al. 2020 [1], Keeping mortality as low as possible will be the highest priority for individuals; hence governments must put in place measures to ameliorate the inevitable economic downturn. The current global picture shows small chains of transmission in many countries and large chains resulting in extensive spread in a few countries, such as Italy, Iran, South Korea, and Japan. Most countries are likely to have spread of COVID-19, at least in the early stages, before any mitigation measures have an impact. The scale of the problem is massive. Here I consider new approaches to improve patient's biological resistance to COVID-19 using stem cells, and how benefit might be scaled and simplified using synthetic stem cells to meet logistical needs within a short time frame.","Med Drug Discov","Metcalfe, Su M","32296777"],"abstract":["Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia associated with rapid virus replication. Arising in Wuhan China December 2019, the current COVID-19 epidemic has rapidly grown with person-to-person infection expanding to become a global health emergency now on pandemic scale. Governments will not be able to minimise both deaths from COVID-19 and the economic impact of viral spread in mitigation of this current COVID-19 pandemic, according to Anderson et al. 2020 [1], Keeping mortality as low as possible will be the highest priority for individuals; hence governments must put in place measures to ameliorate the inevitable economic downturn. The current global picture shows small chains of transmission in many countries and large chains resulting in extensive spread in a few countries, such as Italy, Iran, South Korea, and Japan. Most countries are likely to have spread of COVID-19, at least in the early stages, before any mitigation measures have an impact. The scale of the problem is massive. Here I consider new approaches to improve patient's biological resistance to COVID-19 using stem cells, and how benefit might be scaled and simplified using synthetic stem cells to meet logistical needs within a short time frame."],"journal":"Med Drug Discov","authors":["Metcalfe, Su M"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32296777","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.medidd.2020.100019","keywords":["corona virus","cytokine storm","leukaemia inhibitory factor","mesenchymal stem cells","synthetic stem cells"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China","Italy","Iran","South Korea","Japan"],"countries":["Japan","China","Iran, Islamic Republic of","Italy","Korea, Republic of"],"countries_codes":["JPN|Japan","CHN|China","IRN|Iran, Islamic Republic of","ITA|Italy","KOR|Korea, Republic of"],"_version_":1664641388281593856,"score":83.42478},{"pmid":32292113,"title":"Stem Cell-Based Therapy for Coronavirus Disease 2019.","text":["Stem Cell-Based Therapy for Coronavirus Disease 2019.","The novel coronavirus disease 2019 (COVID-19) has grown to be a global public-health emergency since patients were first detected in Wuhan, China, in December 2019. As of April 9, 2020, the novel coronavirus (named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses on February 11) has infected 83,251 and 1,484,811 patients in China and the world, respectively. However, we have neither confirmed effective antiviral medications nor vaccines available to deal with this emergency. In this commentary, we offer an alternative promising therapy for COVID-19, that is, mesenchymal stem cell transplantation.","Stem Cells Dev","Zhao, Robert Chunhua","32292113"],"abstract":["The novel coronavirus disease 2019 (COVID-19) has grown to be a global public-health emergency since patients were first detected in Wuhan, China, in December 2019. As of April 9, 2020, the novel coronavirus (named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses on February 11) has infected 83,251 and 1,484,811 patients in China and the world, respectively. However, we have neither confirmed effective antiviral medications nor vaccines available to deal with this emergency. In this commentary, we offer an alternative promising therapy for COVID-19, that is, mesenchymal stem cell transplantation."],"journal":"Stem Cells Dev","authors":["Zhao, Robert Chunhua"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32292113","week":"202016|Apr 13 - Apr 19","doi":"10.1089/scd.2020.0071","keywords":["covid-19","clinical trial","transplantation"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China","China"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636192498384896,"score":80.07133},{"pmid":32281052,"title":"Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.","text":["Mesenchymal Stem Cell Therapy for COVID-19: Present or Future.","\"COVID-19\" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing.","Stem Cell Rev Rep","Golchin, Ali","Seyedjafari, Ehsan","Ardeshirylajimi, Abdolreza","32281052"],"abstract":["\"COVID-19\" is the word that certainly isn't forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment for this disease has been discovered to date. Probably, preventing the severe acute respiratory infection form of COVID-19 as the most dangerous phase of this disease can be helpful for the treatment and reduction of the death rate. In this regard, mesenchymal stem cells (MSCs)-based immunomodulation treatment has been proposed as a suitable therapeutic approach and several clinical trials have begun. Recently, MSCs according to their immunomodulatory and regenerative properties attract attention in clinical trials. After the intravenous transplantation of MSCs, a significant population of cells accumulates in the lung, which they alongside immunomodulatory effect could protect alveolar epithelial cells, reclaim the pulmonary microenvironment, prevent pulmonary fibrosis, and cure lung dysfunction. Given the uncertainties in this area, we reviewed reported clinical trials and hypotheses to provide useful information to researchers and those interested in stem cell therapy. In this study, we considered this new approach to improve patient's immunological responses to COVID-19 using MSCs and discussed the aspects of this proposed treatment. However, currently, there are no approved MSC-based approaches for the prevention and/or treatment of COVID-19 patients but clinical trials ongoing."],"journal":"Stem Cell Rev Rep","authors":["Golchin, Ali","Seyedjafari, Ehsan","Ardeshirylajimi, Abdolreza"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281052","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s12015-020-09973-w","keywords":["covid-19","clinical trials","coronavirus","immunomodulatory","mesenchymal stem cell","stem cell therapy"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664636704096518144,"score":77.904945}]}